Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Progenics On Way To The FDA With Second Product Offering Azedra

Executive Summary

Progenics looks set to expand its product portfolio with a mid-year filing expected for its novel radiopharmaceutical product in ultra-rare neuroendocrine tumors following success in a pivotal study conducted under an SPA.

You may also be interested in...



14 Approvals To Look Out For In Q3

As many as 14 new products are up for US approval in the third quarter, research by Informa Pharma's Biomedtracker shows. Scrip takes a look at the candidates and their chances of reaching the market.

Keeping Track: Ilumya, Adcetris Approved; Xtandi Priority Reviewed; Azedra Goal Date Extended

The latest drug development news and highlights from our US FDA Performance Tracker.

AstraZeneca Pushes Into GI Cancers With HIMALAYA And TOPAZ-1

Pivotal data presented at the ASCO GI meeting in liver and biliary tract cancers could add a couple of billion dollars to Imfinzi’s sales and breathe new life into the CTL4 inhibitor tremelimumab.

Topics

Related Companies

UsernamePublicRestriction

Register

SC098494

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel